From NapaJen to Immunohelix: Transitioning to the Next Level

Abstract

Since the discovery of polysaccharide nucleic acid complexes in 2000, NapaJen Pharma Inc. has been established, faced struggles during the COVID-19 pandemic, and has been revitalized with the support of new investor, Remiges Ventures. Recently, the company has renamed its Japanese corporate entity to Immunohelix and is focusing on developing new pipelines. In this article, we want to introduce our foundational technology and discuss what is necessary to transform this basic technology into practical applications through innovation.